Product Detailed Description

liposomal Palmitoylethanolamide 70% PEA — High Bioavailability Pain and Neuroinflammation Supplement

Product Overview

Liposomal Palmitoylethanolamide 70% PEA is a premium-grade dietary supplement ingredient delivering palmitoylethanolamide in an advanced liposomal delivery system. Palmitoylethanolamide (PEA, CAS 544-31-0), also known as palmidrol or N-(2-hydroxyethyl)hexadecanamide, is an endogenous fatty acid amide belonging to the N-acylethanolamine family. It is chemically characterized by the molecular formula C₁₈H₃₇NO₂ and a molecular weight of 299.5 g/mol. PEA occurs as a white to off-white crystalline powder with a purity of ≥98% in pharmaceutical grades.

PEA is a natural plant active substance present in the diet and is also an endogenous cytoprotective lipid. It can be isolated from soy lecithin, egg yolk, and peanut flour, or prepared by chemical synthesis. PEA has a wide range of pharmacological activities, including anti-inflammatory, analgesic, antimicrobial, immunomodulatory, and neuroprotective effects. It is used in the treatment of neurological disorders (Parkinson’s disease, Alzheimer‘s disease, spinal cord injury, stroke), retinopathy (glaucoma and diabetic retinopathy), and pain (chronic inflammatory diseases, neuroinflammatory disorders, migraine and menstrual pain). PEA is sold mainly in the form of powders (micronised and ultra-micronised) or capsules, with powder particle size closely related to bioavailability.

Why Liposomal Technology?

Conventional PEA presents significant formulation challenges. The compound is highly lipophilic and nearly insoluble in water, with a solubility of just 4 mg/L, making it hard for the body to absorb when taken orally. Studies show that most PEA doesn’t enter the bloodstream, resulting in low bioavailability and limiting its potential health benefits. Despite its significant therapeutic potential, the clinical effectiveness of PEA is limited by its poor water solubility and, consequently, low oral bioavailability.

Liposomal encapsulation provides four critical advantages:

1. Dramatically Enhanced Bioavailability — Liposomal PEA utilizes an advanced technology that encapsulates PEA within a double molecular layer of lipids, enhancing the bioavailability of PEA. Compared with regular PEA, the relative bioavailability of liposomal PEA is elevated by 28 times, making it more effective at lower doses. Liposomal delivery systems encapsulate PEA in a lipid bilayer, similar to the body‘s cell membranes, and PEA liposomes exhibit improved absorption into the bloodstream, resulting in enhanced bioavailability and efficacy.

2. Instant Water Dispersibility — Regular PEA is insoluble in water, with evident stratification. Liposomal PEA can be dispersed evenly in water as an emulsion, enabling its use in beverages and liquid formulations. A natural hybrid-hydrogel formulation of PEA demonstrated a 56-fold increase in solubility compared to micronized PEA, with D90 of 523 ± 28 nm and zeta potential of −60 ± 6 mV.

3. Enhanced Gastrointestinal Permeation — A novel liposomal PEA with enhanced gastrointestinal permeating properties demonstrated significant improvement in PEA’s permeability and absorption in an ex vivo simulated gastrointestinal environment. In vitro digestion under simulated gastric fluid and simulated intestinal fluid conditions demonstrated that liposomal PEA significantly enhanced the release pattern of PEA into solution, showing an 8-fold enhancement in gastric release and an overall 7-fold increase in bioaccessibility compared to micronized PEA.

4. Sustained Release — Liposomal formulations provide controlled release of PEA, with increased release and rapid and long-lasting effects compared to conventional PEA.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% PEA by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Liposomal encapsulation achieves 28 times higher relative bioavailability compared to regular PEA, with excellent particle size distribution and an average diameter of 45 nm.

• Endocannabinoid System Support — PEA is an endogenous endocannabinoid receptor agonist and a simple fatty acid amide, originally identified as a food component.

• PPAR-α Mediated Anti-Inflammatory Activity — PEA selectively activates PPAR-α in vitro with an EC50 value of 3.1 ± 0.4 μM and induces the expression of PPAR-α mRNA. In animal models, PEA attenuates inflammation in wild-type mice but has no effect in mice deficient in PPAR-α.

• Clinically Validated for Menstrual Pain — A randomized, double-blind, placebo-controlled crossover study demonstrated that 300 mg of PEA resulted in significant reduction in menstrual pain scores at 1, 1.5, 2, and 2.5 hours post-dosage compared to placebo (p = .045, .009, .015, and .039, respectively).

• Clinically Validated for Endometriosis Pain — A study found that daily supplementation with 800 mg PEA and 80 mg transpolydatin for 90 days significantly reduced endometriosis-related pain.

• Clinically Validated for Chronic Pain — Studies indicate that higher doses (such as 600 mg/day) may be more effective than lower doses (such as 300 mg/day), but the specific dosage should be adjusted according to the individual patient‘s condition.

• Water-Dispersible — Liposomal PEA can be dispersed evenly in water as an emulsion, making it suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated PEA across a range of doses. A randomized crossover trial used 300 mg of PEA at menstrual pain onset, with a second dose permitted after 2 hours if pain persisted. A study found that daily supplementation with 800 mg PEA and 80 mg transpolydatin for 90 days significantly reduced endometriosis-related pain. Studies indicate that higher doses (such as 600 mg/day) may be more effective than lower doses (such as 300 mg/day), but the specific dosage should be adjusted according to the individual patient’s condition. Studies have demonstrated the safety and efficacy of PEA when used as a nutritional therapy for glaucoma up to 1.8 grams per day, with excellent tolerability. The oral administration of one gram of PEA per day has also been reported to have no adverse effects. The LD50 of PEA was found to be greater than the limiting dose of 2000 mg/kg body weight in animal studies. For general pain and neuroinflammation support, 300–600 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.